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ABSTRACT 
Selenium may affect prostate cancer (PC) risk via its plasma carrier selenoprotein P which shows 
dramatically reduced expression in PC tumors and cell-lines.  The selenoprotein P (SEPP1) 
Ala234 SNP allele is associated with lower plasma selenoprotein P in men, reducing the 
concentration/activity of other antioxidant selenoproteins.  Selenium status also modifies the effect 
of mitochondrial superoxide dismutase (SOD2) SNP Ala16Val on PC risk. We investigated the 
relationship of these SNPs with PC risk.   DNA from 2,975 cases and 1,896 age-matched controls 
from the population-based Prostate Cancer in Sweden (CAPS) study were genotyped using 
TaqMan® assays.  Cases were designated aggressive (APC) or non-aggressive (NPC) at diagnosis 
by clinical criteria.  Association with PC was investigated by logistic regression; gene-gene 
interaction using a general linear model.  Mean plasma selenium measured in 169 controls was 
relatively-low (76.0±17.2μg/L).  SNP genotype-distributions were in Hardy-Weinberg 
Equilibrium.  SOD2-Ala16+ men were at greater PC risk (OR 1.19, 95%CI 1.03-1.37) compared 
to SOD2-Val16 homozygotes.  Men homozygous for SEPP1-Ala234 had a higher risk of PC (OR 
1.43, 95%CI 1.17-1.76) and APC (OR 1.60, 95%CI 1.22-2.09) if they were SOD2-Ala16+, rather 
than SOD2-Val16 homozygotes (interaction, PC P=0.05, APC P=0.01).  This interaction was 
stronger in ever-smokers: SOD2-Ala16+ men homozygous for SEPP1-Ala234 had an almost 
doubled risk of PC (OR 1.97, 95% CI 1.33-2.91; interaction P=0.001).  In a low selenium 
population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at increased risk of PC/APC 
especially if ever-smokers, because they are likely to produce more mitochondrial H2O2 that they 
cannot remove, thereby promoting prostate tumor-cell proliferation and migration.   
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INTRODUCTION 
Selenium, an essential nutrient, may reduce the incidence and/or progression of prostate cancer 
particularly in men with the relatively-low baseline selenium status commonly found in Europe 
[1-4].  The potential anti-cancer effects of selenium may be exerted through a number of parallel 
mechanisms some of which involve the selenoproteins[1].  Indeed recent evidence suggests an 
important role for selenoproteins in cancer[1, 5], specifically in prostate cancer [6]. 
Selenoprotein P contains at least 40% of the total selenium in plasma [7].  Deletion of the 
gene for selenoprotein P in mouse models alters the distribution of selenium in body tissues 
suggesting that selenoprotein P is required for selenium transport [8, 9].  While the human 
selenoprotein P gene (SEPP1) is abundantly expressed in normal colon mucosa, there is a 
significant reduction or loss of SEPP1 mRNA expression in colon cancers [10].  Expression of 
SEPP1 is also dramatically reduced in a subset of human prostate tumors, mouse tumors and in the 
androgen-dependent (LNCaP) and androgen-independent (PC-3) prostate cancer cell lines [11].  
Homozygosity for the Ala234 allele of the SEPP1 Ala234Thr SNP (rs3877899) is associated with 
a lower concentration of plasma selenoprotein P in men, affecting the concentration and/or activity 
of other selenoproteins, notably of thioredoxin reductase 1 (TR1) and some of the antioxidant 
glutathione peroxidases (GPx) [12].  Thus it is conceivable that SEPP1 genotype may affect 
prostate cancer risk. 
Selenium status is linked to the effect of another polymorphism on prostate cancer risk i.e. 
that of mitochondrial superoxide dismutase (SOD2 or MnSOD) [13], the major detoxifying 
enzyme in the mitochondrion.  This enzyme dismutes superoxide to H2O2, which must itself then 
be detoxified to water by GPx [13].  A well-characterized polymorphism in SOD2 results in the 
substitution of alanine (Ala) for valine (Val) at codon 16 (rs4880) and a higher activity of the 
Ala16 mitochondrial enzyme [14].  Among US men homozygous for Ala16, those whose plasma 
selenium was in the top quartile had a relative risk (RR) of prostate cancer of 0.3 (95% CI 0.2 to 
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0.7) and of clinically aggressive prostate cancer of 0.2 (95% CI 0.1 to 0.5) when compared with 
those whose plasma selenium was in the bottom quartile [13].  The dependence on selenium status 
of this genotype effect on prostate cancer risk may relate to the requirement for adequate GPx to 
remove the extra H2O2 formed in Ala16 homozygotes [13].   
We investigated the relationship of these two putatively-functional polymorphisms to 
prostate cancer risk in the large CAPS (CAncer Prostate in Sweden) study [15].  We hypothesised 
that in a low selenium environment, as in Sweden, men who have SNP alleles that both reduce 
their ability to make functional selenoprotein P (SEPP1 Ala234 homozygotes) and increase their 
production of H2O2 (SOD2 Ala16) thereby increasing their requirement for GPx, would have a 
greater risk of prostate cancer than men who do not have these alleles. 
 
SUBJECTS AND METHODS 
Participants 
The CAPS study is a large-scale, population-based, prostate cancer case-control study, which has 
been extensively described in previous work [15, 16].  The inclusion criterion for cases was a 
newly diagnosed, pathologically or cytologically verified adenocarcinoma of the prostate.  In total, 
3,648 prostate cancer patients were invited to participate in the study and 3,161 (87%) agreed.  
DNA samples were obtained from a total of 2,975 cases, for which the corresponding clinical data 
and completed demographic questionnaires were available.  Cases were classified as either non-
aggressive at diagnosis (tumor stage 1 and 2, Gleason score < 8, Differentiation G1–G2, N0/NX, 
M0/MX, PSA < 100 μg/L) or aggressive at diagnosis (tumor stage 3-4, Gleason score ≥ 8, 
Differentiation G3–G4, N+, M+,  PSA ≥ 100 μg/L) [15].  Controls matching the case distribution 
for age (within 5 year bands) and geographical region were randomly selected from the Swedish 
Population Registry.  A total of 3,153 controls were invited to participate of whom 2,149 agreed.  
DNA and completed questionnaires were obtained from a total of 1,896 controls, giving a 
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response rate of over 88%.  Written informed consent was obtained from all participants and study 
was approved by the research ethics committees at the Karolinska Institutet and Umeå University 
Hospital.  The University of Surrey research ethics committee approved this genetics study. 
Genotyping  
DNA was extracted from leukocytes using a Puregene kit (Gentra Systems, Minneapolis MN).  
All genotyping was performed using TaqMan® assays and the operator was blinded to 
case/control status.  Controls of known genotype for each of the polymorphisms investigated were 
included in the assay.  Non-template controls and duplicate samples were incorporated for quality 
control purposes. SOD2 Ala16Val (rs4880) PCR primers and dual-labelled, allelic probes were 
designed and manufactured by Applied Biosystems Inc (CA, USA).  Primer and probes were as 
follows: forward GCTGTGCTTTCTCGTCTTCAG, reverse CTGCCTGGAGCCCAGATAC, 
Ala16 Probe VIC-CCAAAGCCGGAGCC-TAM, Val16 probe FAM-CCCAAAAGCCGGAGCC-
TAM.  SEPP1 Ala234Thr (rs3877899) was genotyped using a pre-designed assay (TaqMan® 
Assay number C_2841533_10) so primer and probe details are not available but the Ala234 allele 
was detected with VIC and  the Thr234 allele with FAM.  Each reaction (12.50 µl) contained 2–10 
ng of DNA, 1 x PCR master mix (ABgene, Epsom, UK), 1 x TaqMan® assay mix (working 
concentration of dual labelled probes 100 nM each and PCR primer 900 nM).  Reactions were 
incubated as specified by the manufacturer: 95°C for 15 min, 40 cycles of 95°C for 15 sec and 
60°C for 1 min.  Fluorescence was measured and genotypes assigned using the ABI prism 7500 
and associated software (Applied Biosystems Inc, CA, USA).   
Plasma selenium measurement 
EDTA plasma samples from 169 controls were stored at -80°C prior to determination of 
selenium by dynamic reaction cell inductively coupled plasma mass spectrometry (DRC ICP-MS) 
using an Elan 6100 DRC plus (SCIEX Perkin-Elmer).  78Selenium was measured, employing 
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methane (at 0.5 ml/min) as the DRC gas to remove the argon dimer background [17] and butanol 
to increase the sensitivity of the signal [18]. Within the plasma Se concentrations used in this 
study, the within-run coefficient of variation (CV) was 2.1-2.6% while the between-run CV was 
3.1-5.6% (n=10).  Accuracy was assured by analysis of four internal quality control serum 
samples (TEQAS, University of Surrey, Guildford) and certified reference materials: Seronorm 
Serum (Nycomed, Norway) JL4409, mean value (5 determinations) 0.90, SD 0.04 µmolL-1 
(certified 0.92, range 0.84 – 1.00) µmolL-1, and NO0371 mean value (5 determinations) 1.76, SD 
0.04 (certified 1.72, range 1.61-1.83) µmolL-1.  The detection limit was less than 0.01µmolL-1. 
Data analysis 
All data were analyzed using SPSS v13.  Continuous variables were shown to be normally 
distributed.  The Pearson Chi squared test was used to compare observed SNP genotype 
frequencies with those expected under conditions of Hardy-Weinberg equilibrium. Logistic 
regression models were used to assess the association between SNP genotypes and prostate cancer 
risk, with genotypes coded either as number of rare alleles (0, 1, 2) or as minus allele/plus allele 
(0, 1) as appropriate, with adjustment for the possible confounding factors age and geographical 
location. Genotype-specific risks were estimated as adjusted odds ratios (OR) with associated 95% 
confidence intervals (CI) by logistic regression. The interaction between the two SNPs in 
determining prostate cancer risk was assessed using a general linear model, again adjusting for age 
and geographical region, with genotypes coded as minus allele/plus allele (0, 1).  Data analysis 
was performed separately in cases with non-aggressive or aggressive disease, and in ever- and 
never-smokers. A two-tailed P value of less than 0.05 was considered statistically significant.   
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RESULTS 
Selenium status 
The mean (±SD) plasma selenium was 76.0 ± 17.2 μg/L in 169 CAPS control samples confirming 
the expected relatively-low selenium status of this group of Swedish men.  There was no 
difference in selenium status between genotypes or by smoking status. 
 
SNP genotyping 
Through the blinded genotyping of duplicated samples, genotyping error rates were less than 
1.5%.  Both the SOD2 Ala16Val and SEPP1 Ala234Thr polymorphisms were shown to be in 
Hardy Weinberg equilibrium and the allele frequencies within the control population were 
comparable to those in other published data (NCBI SNP database www.ncbi.nlm.nih.gov/SNP and 
for example [12, 13]).  
 
SOD2 and SEPP1 genotypes and prostate cancer risk  
Individuals with at least one SOD2 Ala16 allele (SOD2 Ala16+) had an almost 20% increased risk 
of prostate cancer compared to Val16 homozygotes (adjusted OR 1.19; 95% CI 1.03 to1.37; P = 
0.02; Table 1).  No association between SEPP1 Ala234Thr genotype and prostate cancer risk was 
observed.  The association between the SOD2 polymorphism and either non-aggressive or 
aggressive disease was of similar magnitude to that with all prostate cancer (non-aggressive plus 
aggressive) (Table 1).  There was no association between SEPP1 genotype and either non-
aggressive or aggressive disease.   
 
Interaction between SOD2 and SEPP1 polymorphisms 
Men homozygous for the SEPP1 Ala234 allele, who were also SOD2 Ala16+, were at 43% greater 
risk of prostate cancer than SOD2 Val16 homozygotes (adjusted OR 1.43; 95% CI 1.17 to 1.76; P 
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= 0.0005; Table 2, Fig. 1).  By contrast, there was no association between SOD2 genotype and 
cancer risk in SEPP1 Thr234+ men.  This interaction between the two SNPs in determining risk of 
prostate cancer had a borderline statistically significant P value of 0.05.  
In aggressive prostate cancer, the interaction between the SNPs was stronger (P = 0.01) 
with SEPP1 Ala234 homozygotes who were also SOD2 Ala16+ having a 60% increased risk of 
aggressive disease compared to SOD2 Val16 homozygotes (adjusted OR 1.60; 95% CI 1.22, 2.09; 
P = 0.0007; Table 2, Fig. 1), whereas there was no association with SOD2 genotype in the SEPP1 
Thr234+ men.  Although, the association with SNP genotypes in non-aggressive disease might 
appear significant, the interaction between the two SNPs was far from statistical significance as 
demonstrated by the broad overlap between the odds ratio confidence intervals in the two SEPP1 
genotype groups (Table 2).   
  
Impact of smoking on the SOD2 and SEPP1 associations with prostate cancer risk  
Although smoking status was not available for all subjects, given the known effect of smoking on 
antioxidant status, we investigated the effect of genotype on prostate cancer risk in the subset of 
participants (CAPS1 [15]) for whom smoking data were available (Table 3).  Neither SOD2 nor 
SEPP1 genotype taken separately significantly affected the risk of prostate cancer in either never- 
or ever-smokers.  The odds ratio associated with the SOD2 Ala16+ ever-smokers (Table 3) was, 
however, similar in magnitude to that in the group as a whole (Table 1) although the association 
did not reach statistical significance.  
 The interaction between SEPP1 and SOD2 SNPs in determining prostate cancer risk was 
modified by smoking status (Table 4, Fig. 1).  Ever-smokers homozygous for SEPP1 Ala234 had a 
highly-significant two-fold increase in prostate cancer risk if they were also SOD2 Ala16+ (OR 
1.97; 95% CI 1.33, 2.91; P = 0.0007).  The association between SOD2 genotype and cancer risk in 
ever-smokers was not observed in SEPP1 Thr234+ men (OR 0.75; 95% CI 0.47, 1.18; P = 0.21).  
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This interaction between SEPP1 and SOD2 SNPs in determining prostate cancer risk in ever-
smokers was highly significant (P = 0.0014) contrasting with the lack of interaction found in 
never-smokers (P = 0.43).  
 
 
DISCUSSION 
The mean plasma selenium of  76.0 ± 17.2 μg/L in control samples confirms  the relatively low 
selenium intake and status in the Swedish population (cf mean US value of 125 μg/L determined 
in the Third National Health and Nutrition Examination Survey [19]).  This value is less than the 
92 μg/L required for maximal plasma GPx activity [20] and considerably less than the plasma 
concentration required for full expression of SEPP1 [7, 21], demonstrating that the study 
population has a selenium intake inadequate for optimal selenoprotein synthesis and/or activity.  
This may be relevant to prostate cancer risk since low selenoprotein production led to higher-
grade lesions and aggressive disease in a transgenic mouse model of prostate cancer [6].  We 
reasoned that in a population with relatively-low selenium status, inter-individual variation in 
selenium requirement, as determined by selenoprotein genotype, might have a greater effect on the 
risk of prostate cancer than in a selenium-replete population. 
Despite our rationale, we found no effect of SEPP1 genotype per se on the risk of prostate 
cancer or on non-aggressive or aggressive prostate cancer.  A similar null-effect of this genotype 
was found in colorectal cancer [10].  We did, however, find an effect of genotype in a pathway 
associated with selenoprotein function: although SOD2 is not a selenoprotein, the product of its 
activity, H2O2, is a substrate for GPx.  The Val16Ala SNP in SOD2 has been shown to alter the 
secondary structure of the mitochondrial import sequence of the superoxide dismutase protein 
such that the Ala16 variant is imported more efficiently into the mitochondrial matrix, resulting in 
higher enzyme activity [22].   Individuals with at least one SOD2 Ala16 allele (Ala16+) therefore 
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generate more active superoxide dismutase (and therefore more H2O2) than those homozygous for 
the Val16 variant.  In our study, SOD2 Ala16+ men were at a 19% increased risk of prostate 
cancer compared to Val16 homozygotes (Table 1).  The mitochondrion contains little or no 
catalase and so is entirely dependent on the activity of GPx to remove H2O2  [23], though of course 
H2O2 is sufficiently long-lived to diffuse out of the mitochondrion.   
H2O2 promotes prostate cancer cell proliferation and migration [24, 25], and induces 
matrix metalloproteinases required for tumor invasion [26, 27].  For instance, H2O2 levels rose in 
cell-lines of the LNCaP series as tumorigenic and metastatic potential increased [24]. 
Furthermore, addition of ebselen, a GPx mimetic, to the assay completely abolished the 
chemiluminescence attributable to H2O2 [24].  At low selenium concentration where there is 
insufficient GPx activity to remove H2O2, the SOD2 16Ala allele would therefore be expected to 
have a deleterious effect owing to the higher H2O2  production associated with that allele variant.  
Our population has a mean plasma selenium concentration well below the level required to fully 
optimise GPx (as plasma GPx) [20] making our observation consistent with predictions.   
Furthermore, the mean selenium concentration in our study was below the bottom of the 
range of plasma selenium (84-131 μg/L) in the study in which Li et al [13] reported an association 
between SOD2 Ala16Val genotype and prostate cancer risk when subjects were divided according 
to quartile of selenium status.  In that study, high selenium status was advantageous for SOD2 
Ala16 homozygotes as the combination of high SOD2 activity in the mitochondrion, together with 
high selenium/GPx, enabled efficient removal of both reactive oxygen species, superoxide and 
H2O2.  By contrast, Ala16 homozygotes were at increased risk, particularly of aggressive prostate 
cancer, when their selenium status was in the bottom quartile [13].  While we saw an overall effect 
of SOD2 Ala16Val genotype in our low-selenium population, Li et al [13] observed no overall 
effect, perhaps because the range of selenium status in their population encompassed both positive 
and negative effects of SOD2 genotype on prostate cancer risk leading to a null effect overall.  
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Our findings might help explain why the SOD2 Ala16Val risk allele appears to vary from study to 
study in a number of cancers and illustrates a gene-nutrient interaction where the effect of 
genotype on risk reverses with change in nutrient status of the population.   
Results from the ATBC study may further illustrate this point.  Finnish smokers who were 
SOD2 Ala16 homozygotes had a 70% increased risk of prostate cancer when compared to Val 
homozygotes [28].  This is consistent with the findings of Li et al in their lowest selenium quartile 
where the SOD Ala16 homozygotes had an increased risk of prostate cancer [13] and suggests that 
men from the ATBC cohort must have had a similar selenium status to the bottom quartile of US 
men.  Although at first sight this might seem surprising since the cohort was recruited after the 
introduction of selenium-enriched fertilizers in Finland, in fact there are data to show that the 
ATBC study did indeed include men with very low Se status [29].  When the use of selenized 
fertilisers was implemented in 1984, mean plasma selenium in Finland was 70 μg/L.  However, 
selenium status did not peak until 1990, reaching a maximum of 120 g/L (cf mean US value 125 
μg/L [19]), before declining to 90 g/L in 1999 [30].  Thus the mean selenium status of this 
Finnish cohort, recruited from 1985-88 and followed up until death or 1993, would have been 
considerably lower than that of the US men and would certainly have been lower during the time 
this slow-growing cancer was developing, prior to the initiation of the selenized fertilizer program.  
We found evidence for a gene-gene interaction between the Ala234Thr polymorphism in 
the Se transport protein, SEPP1, and the SOD2 Val16Ala polymorphism.  Individuals 
homozygous for SEPP1 Ala234, SOD2 Ala16+ were 43% more likely to have prostate cancer 
compared to Val16 homozygotes (Table 2); this interaction was stronger in aggressive disease 
resulting in a 60% increased risk.  Prospective cohort studies have shown a stronger association 
between selenium status and risk of aggressive than localized disease [31-35]. 
Of relevance to our findings, Méplan et al recently found that male SEPP1 Ala234 
homozygotes had lower plasma selenoprotein P than heterozygotes, with an associated trend for 
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reduced activity or protein concentration of GPx1 (cytosolic GPx) and GPx4 (phospholipid GPx) 
[12].  The authors suggest that the Ala234Thr polymorphism affects the stability of selenoprotein 
P, possibly through a post-translational modification, affecting protein levels only when selenium 
intake is suboptimal.  Thus genotype-dependent differences in plasma selenoprotein P 
concentration were only observed under relatively low selenium conditions and disappeared after 
supplementation with selenium [12].  Our observations in a population of relatively-low selenium 
status are consistent with those findings.  
 Because there is strong evidence that selenoprotein P plays a critical role in delivery of 
hepatic selenium to other tissues [8, 9, 36], we hypothesise that men homozygous for the SEPP1 
Ala234 allele have reduced availability of selenium for the production of GPx in the prostate.  
This would impede the ability of the prostate to remove H2O2 and protect against prostate cancer 
[24, 25] (Fig. 2).  In our study, this polymorphism only affected prostate cancer risk in conjunction 
with the SOD2 Ala16 allele, which, by allowing more efficient transport of superoxide dismutase 
into the mitochondrion, caused increased production of H2O2 that became detrimental in the face 
of low selenium. The gene-gene interaction between the SEPP1 Ala234Thr and SOD2 Val16Ala 
polymorphisms was also apparent in current or ex-smokers who had a two-fold increased risk of 
prostate cancer compared with SOD2 Val16 homozygotes (Table 4).  As we have postulated that 
the mechanism by which these polymorphisms have their combined effect is oxidative-stress 
related, the greater strength of the interaction in smokers than in the study as a whole, despite 
smaller numbers, might be explained by an exacerbation of oxidative stress in ever-smokers 
though it may equally well be related to the lower selenium status seen in smokers [37, 38].  In 
fact we did not observe lower selenium status among smokers in our study but this may have been 
due to the small number (n=169) of plasma selenium measurements made. 
Our study has limitations in that HapMap (www.hapmap.org) shows considerable linkage 
disequilibrium (LD) at both these gene loci so we cannot be sure that these polymorphisms are the 
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only functional SNPs affecting risk of prostate cancer in the SOD2 and SEPP1 genes.  However, 
given the published studies implying functional consequences of the amino-acid changes, it would 
seem plausible that they have some function in this context.  Both of these SNPs were included in 
the recent genome-wide screen of a subset of our case-control study (498 aggressive cases and 494 
controls) and results are consistent with the present data on a larger sample [39]. Other recent 
genome-wide SNP screens in prostate cancer have not implicated either of these genes [40-42], 
but the UK study did find an associated SNP (rs9364554) in the SLC22A3 gene [40] on 
chromosome 6, just over 700kb telomeric of SOD2. Analysis of HapMap CEPH data reveals no 
LD between this SNP and SOD2 Val16Ala, suggesting that the SOD2 SNP is independently 
associated with prostate cancer risk and is not acting as a marker for SLC22A3 association. 
If confirmed, the evidence presented here would allow identification of individuals who 
would particularly benefit from selenium supplementation to prevent prostate cancer.  Among the 
Swedish men in our study, 41% had the high risk genotype combination (homozygosity for SEPP1 
Ala 234 and possession of an SOD2 Ala16 allele).  Similar allele frequencies have been identified 
in other populations of European descent (NCBI SNP database www.ncbi.nlm.nih.gov/SNP/ and 
for example [12, 13]).  We have observed the combined effect of the SOD2 Val16Ala and SEPP1 
Ala234Thr SNPs under conditions of limited selenium availability.   Such an effect can probably 
not be observed in areas of higher selenium status such as North America where plentiful 
selenium supply can probably obviate the disadvantage of homozygosity for SEPP1 234 Ala 
except for those with the lowest intakes [13].  Optimising the selenium intake of individuals 
homozygous for SEPP1 Ala234 will improve their ability to supply selenium via selenoprotein P 
for GPx synthesis and H2O2 removal [12].  Confirmation of our findings in other populations with 
low selenium intake should be a high priority.  So far, few genetic tests have had the potential to 
ameliorate risk by identifying the need for a simple, inexpensive, nutritional supplement. 
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 Table 1.  The relationship between SNPs in two genes, SOD2 (Val16Ala) and SePP1 (Ala234Thr) with risk of all prostate cancer, non-
aggressive prostate cancer and aggressive prostate cancer in the CAPS study. 
 
 
*odds ratio adjusted for age and geographical location, 95% confidence interval 
n = Number of subjects 
 
 
 Controls All prostate cancer Non-aggressive prostate cancer Aggressive prostate cancer  
Genotype n n OR (95% CI)* P n OR (95% CI)* P n OR (95% CI)* P 
SOD2 Codon 16 1636 2634   1648   986   
      Val/Val 423  602 Referent  382 Referent  220 Referent  
      Ala/Val 789  1352 1.21 (1.03 to 1.41) 0.02 854 1.21 (1.02 to 1.44) 0.03 498 1.21 (0.99 to 1.48) 0.60 
      Ala/Ala 424 680 1.15 (0.97 to 1.37) 0.11 412 1.11 (0.91 to 1.36) 0.29 268 1.22 (0.98 to 1.53) 0.78 
      Ala/Val + Ala/Ala 1213  2032 1.19 (1.03 to 1.37) 0.02 1266 1.18 (1.00 to 1.38) 0.05 766 1.21 (1.01 to 1.46) 0.04 
SEPP1 Codon 234 1570 2643   1653   990   
      Ala/Ala 878 1522 Referent  951   571 Referent  
      Ala/Thr 595 949 0.94 (0.82 to 1.07) 0.37 593 0.95 (0.82 to 1.11) 0.54 356 0.93 (0.79 to 1.10 0.40 
      Thr/Thr 97 172 1.09 (0.83 to 1.42) 0.54 109 1.13 (0.84 to 1.52) 0.42 63 1.03 (0.74 to 1.44) 0.86 
      Ala/Thr + Thr/Thr 692 1121 0.96 (0.85 to 1.09) 0.54 702 0.98 (0.85 to 1.13) 0.76 419 0.94 (0.80 to 1.11) 0.48 
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Table 2.  The interaction between SOD2 Val16Ala and SEPP1 Ala234Thr SNPs and risk of all prostate cancer, non-aggressive prostate cancer 
and aggressive prostate cancer in the CAPS study.  
 . 
 
 
*odds ratio adjusted for age and geographical location, 95% confidence interval 
n = Number of subjects 
 
 Controls All prostate cancer Non-aggressive prostate cancer Aggressive prostate cancer  
Genotype n n OR (95% CI)* P n OR (95% CI)* P n OR (95% CI)* P 
SEPP1 Codon 234 Ala/Ala 816 1360   854   506   
 SOD2 Val/Val 224 286 Referent 1 189 Referent 1 97 Referent 1 
 SOD2 Ala/Val + Ala/Ala 592 1074 1.43 (1.17 to 1.76) 0.0005 665 1.36 (1.09 to 1.71) 0.0073 409 1.60 (1.22 to 2.09) 0.0007 
SEPP1 Codon 234 Ala/Thr + Thr/Thr 638 1009   631   378   
 SOD2 Val/Val 161 246 Referent 1 147 Referent 1 99 Referent 1 
 SOD2 Ala/Val + Ala/Ala 477 763 1.06 (0.84 to 1.34) 0.62 484 1.14 (0.87 to 1.48) 0.35 279 0.95 (0.71 to 1.28) 0.75 
P for interaction  0.051 0.278 0.012 
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Table 3.  The relationship between SNPs in two genes, SOD2 (Val16Ala) and SePP1 (Ala234Thr) with risk of prostate cancer, in never-
smokers and ever-smokers in the CAPS study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*odds ratio adjusted for age and geographical location, 95% confidence interval   
n = Number of subjects 
 
Never-Smokers Ever-Smokers 
Genotype Controls (n) Cases (n) OR (95% CI)* P Controls  (n) Cases (n) OR (95% CI)* P 
SOD2 Codon 16 314 526   487 777   
        Val/Val 75 115 Referent 1 131 178 Referent 1 
        Ala/Val 160 278 1.12 (0.79 to 1.59) 0.53 230 388 1.23 (0.93 to 1.64) 0.15 
        Ala/Ala 79 133 1.11 (0.74 to 1.67) 0.61 126 211 1.23 (0.89 to 1.70) 0.21 
        Ala/Val + Ala/Ala 239 411 1.12 (0.80 to 1.56) 0.52 356 599 1.23 (0.94 to 1.61) 0.12 
SEPP1 Codon 234 260 452       
        Ala/Ala 145 259 Referent 1 225 417 Referent 1 
        Ala/Thr 103 164 0.89 (0.65  to 1.23) 0.49 146 234 0.89 (0.68 to 1.17) 0.41 
        Thr/Thr 12 29 1.38 (0.68 to 2.78) 0.37 24 30 0.79 ( 0.45 to 1.40) 0.43 
        Ala/Thr + Thr/Thr 115 193 0.94 (0.69 to 1.28) 0.71 170 264 0.88 (0.68 to 1.14) 0.33 
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Table 4.  The interaction between SOD2 Val16Ala and SePP1 Ala234Thr SNPs in determining prostate cancer risk in never-smokers and ever-
smokers in the CAPS study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*odds ratio adjusted for age and geographical location, 95% confidence interval 
n = Number of subjects 
 
 
 
 
 Never-Smokers Ever-Smokers 
Genotype Controls (n) Cases (n) OR (95% CI)* P Controls  (n) Cases (n) OR (95% CI)* P 
SEPP1 Codon 234  Ala/Ala 142 252   219 396   
       SOD2  Val/Val 38 51 Referent 1 67 73 Referent 1 
       SOD2  Ala/Val + Ala/Ala 104 201 1.44 (0.89 to 2.34) 0.14 152 323 1.97 (1.33 to 2.91) 0.0007 
SEPP1 Codon 234  Ala/Thr   + Thr/Thr 111 189   167 257   
       SOD2  Val/Val 27 43 Referent 1 39 73 Referent 1 
       SOD2  Ala/Val + Ala/Ala 84 146 1.08 (0.62 to 1.87) 0.80 128 184 0.75 (0.47 to 1.18) 0.21 
P for interaction    0.43    0.0014 
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Figure Legends 
 
Figure 1:  The interaction between SOD2 Val16Ala and SEPP1 Ala234Thr SNPs and risk of: A all prostate cancer; B aggressive prostate 
cancer; C prostate cancer in never-smokers and D prostate cancer in ever-smokers, in the CAPS study. OR = odds ratio, adjusted for age and 
geographical location. R indicates the referent group (foreground column) for each comparison with the alternative SOD2 genotype group 
(background column). 
 
Figure 2: Postulated mitochondrial mechanism for the interaction between SEPP1 and SOD2 polymorphisms and the risk of prostate cancer.  
Possession of a SOD2 Ala16 allele promotes higher import of mitochondrial superoxide dismutase to the mitochondrion resulting in higher 
activity and greater production of H2O2 than with the SOD2 Val16 variant. The availability of selenium for the production of GPx in the prostate, 
already low in the Swedish population, is further reduced in men homozygous for the SEPP1 Ala 234 allele, reducing the ability of the prostate 
to protect against excess hydrogen peroxide (promoter of cell proliferation and migration[24, 25]) and cancer. 
 
